Skip to content
  1. Home/
  2. Latest news/
  3. Innovation/
  4. Award criteria
speaker

Award criteria

About the award:

The Scholars Award is a three-year award in the gross amount of $150,000, which will be paid to the University (the “Recipient”) for the benefit of the Johnson & Johnson Scholar and her research, with the understanding that the Recipient will administer the funds. The Scholars Award will be paid in three (3) installments of U.S. $50,000 per year of the three-year scholarship period, payable in 2022, subject to compliance with the terms and conditions of the program’s Agreement. Winners achievements will also be showcased at a symposium.

The following award criteria applies:

Standards for evaluation:

Judges will use the following criteria to evaluate the applications:

  • Scientific/technical expertise exhibited
  • Novelty/innovation of the research
  • Potential impact of the research
  • Feasibility of the research

You must be a woman working in the field(s) of Science, Technology, Engineering, Mathematics, Manufacturing and Design (STEM2D).

You must be an early to mid-career women working within a STEM2D university department at the time of application at an accredited academic university, institution or design school. Examples include a non-tenured assistant professor, assistant professor or associate professor.

The female scholar should have a minimum degree for the appropriate field:

  • Science; M.D., Ph.D.
  • Technology; Ph.D.
  • Engineering; Ph.D.
  • Math; M.S., Ph.D.
  • Manufacturing; Ph.D.
  • Design; M.A., M.S., MDes, MArch, MFA, MLA, Ph.D.

WiSTEM2D Scholars Award

The Johnson & Johnson WiSTEM²D Scholars Award Program will help develop female leaders and support innovation in STEM fields.

More from Johnson & Johnson

Johnson & Johnson named to Fortune’s 2025 America’s Most Innovative Companies list

The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.